Navigation Links
YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
Date:2/10/2011

e, 47% achieved a minimum 50% decrease in palpable spleen size, qualifying for Clinical Improvement (CI) per IWG-MRT criteria. - CYT387 controlled constitutional symptoms in a significant percentage of patients (night sweats: 88%, bone pain 80%, pruritus: 92%, fever: 100%). - Of 42 subjects who were evaluable for anemia response, 50% had achieved CI as per IWG-MRT criteria. A 57% response rate was observed in transfusion-dependent patients. - Full enrollment of 140 patients into the trial is anticipated in calendar Q1 2011. To date, 111 patients have been enrolled into the study. The Company anticipates that an additional set of updated interim data will be reported in the second quarter of calendar 2011 and a full data set will be reported by the end of calendar 2011. The Company is also working towards completing in calendar 2011 any preclinical and manufacturing activities required to enable CYT387 to commence a Phase III pivotal trial in calendar Q1 2012.

Nimotuzumab:

- Daiichi Sankyo Co., Ltd., CIMYM's licensee for nimotuzumab in Japan, previously initiated a randomized trial with nimotuzumab in second line gastric cancer, together with Kuhnil Pharma Co. Ltd., CIMYM's licensee in Korea. Data from this trial were presented in January 2011 at the ASCO Gastrointestinal Cancers Symposium and demonstrated an improvement in Progression Free Survival in a subset of patients whose tumors were EGFR-positive. Should Daiichi Sankyo indicate an interest in advancing nimotuzumab into a Phase III clinical trial in gastric cancer, it could initiate in calendar 2012 subject to achieving commercial-scale production. Daiichi Sankyo also launched a Phase II trial in first-line treatment of advanced NSCLC for which YM has been advised that recruitment has been completed, with data expected during the first half of calendar 2011. - Oncoscience AG (OSAG), CIMYM's licensee for Europe, has advised that data from a Phase III trial in adult glioma patients may be repor
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
8. YM BioSciences Closes Public Offering of Common Shares
9. YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING
10. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
11. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
(Date:8/28/2014)... PA (PRWEB) August 28, 2014 The ... create a culture that will allow individuals to perform ... becoming increasingly important for employers looking to compete in ... industries are embracing this trend, as the sector increasingly ... of a company, which will have real results on ...
(Date:8/28/2014)... Exciting new work by a Florida State University ... that can take your temperature, emit white light, and ... the molecule looks like a butterfly. , Biwu Ma, ... Engineering in the FAMU-FSU College of Engineering, created the ... has continued to discover that his creation has many ...
(Date:8/28/2014)... Diego, CA (PRWEB) August 28, 2014 ... Pipette.com is offering a promotion for Eppendorf ... Pipette.com customers to purchase the highest quality tubes ... Tubes are ideal for customers doing chemical, medical, ... lab technicians who are not regularly able to ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... 15, 2011 This evening, Novo Nordisk awarded sponsorships ... support programs that educate people living with type 2 ... reduce the risk of long-term diabetes related complications. The ... program – a new initiative that aims to promote ...
... 15, 2011 Roka Bioscience announced today that the ... certification of the Listeria Detection Assay. This evaluation is ... (AOAC-RI) certification of methods used in the food safety ... laboratory and monitored by AOAC. The internal portion of ...
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... leading Chinese pharmaceutical company, today announced that Shanghai ... and Hengrui have entered into a strategic partnership ...
Cached Biology Technology:Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 2Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 3Roka Bioscience Initiates External Trial for AOAC Certification 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 3
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... as the prolific bloomer Emiliania huxleyi , can ... The finding contradicts the common view that E. ... scarce supplies of thiamine in the ocean to survive. ... the ocean," says CIFAR Senior Fellow Alexandra Worden ... with CIFAR fellows John Archibald (Dalhousie University), ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Assortativity signatures of transcription factor networks contribute to robustness 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... Smart Search & Match,the leading provider of high-performance ... has joined the company as Product Marketing Manager. ... 15 years of product and marketing management,experience to ... many high-tech products and solutions worldwide. He has ...
... 2008 An international research team led by Tim ... the director of the School of Medicine,s Center for ... alternative splicing, the process by which single genes produce ... that curing the more than half of genetic diseases ...
... what they think may be a basic recipe for ... stem cells from essentially any mammal, including cows, pigs ... December 26th issue of the journal Cell , ... demonstrated to work in mice earlier this year, which ...
Cached Biology News:Case Western Reserve finds mechanism underlying alt. splicing of premessenger RNA into messenger RNA 2Case Western Reserve finds mechanism underlying alt. splicing of premessenger RNA into messenger RNA 3Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests 2Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests 3
... Storage: The kit is stable for 12 months ... contents of the kit cold. , ,Principle: ... silica-gel based membrane which selectively adsorbs up to ... specialized binding buffers. Nucleotides, oligos ( , ,Application: ...
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
... Leu DAP FLISP Assay with FAM-Labeled ... nm) • Accurately measure serine protease ... permeabilization • B-Bridge's FLISP Kits utilize ... proteases (FLISPs) to measure chymotrypsin-like activity ...
... instrument is the cycler that revolutionized ... uniformity and swappable blocks ensure consistent ... This rugged machine is more than ... for new features and upgrades as ...
Biology Products: